LCMD

LCMD compiles metabolomic data from mass spectrometry-based lung cancer studies, providing a curated collection of 2,013 metabolites from 65 studies to support analysis of metabolic alterations and discovery of diagnostic biomarkers.

Key Features:

• Metabolite collection: Compiles 2,013 metabolites identified in 65 mass spectrometry-based lung cancer studies.
• Quantitative metrics: Reports fold change values comparing cancerous to normal states for identified metabolites.
• Statistical significance: Includes p-values for differential metabolite changes reported in source studies.
• Study metadata: Records specimen type, mass spectrometry method, data processing software, and differential analysis techniques for each study.
• Graphical summaries: Provides graphical summaries of study findings to support interpretation and comparison.
• Data integration: Integrates diverse mass spectrometry-based datasets into a consolidated resource for cross-study comparisons.

Scientific Applications:

• Biomarker discovery: Supports identification and evaluation of metabolites as diagnostic biomarkers for lung cancer.
• Mechanistic analysis: Enables investigation of metabolic alterations to dissect pathogenic mechanisms of lung cancer.
• Comparative analysis: Facilitates cross-study and cross-specimen comparisons of metabolomic profiles derived from different mass spectrometry methods.

Methodology:

Aggregates metabolite identifications and associated quantitative metrics (fold changes and p-values) from 65 mass spectrometry-based lung cancer studies, compiles study-level metadata (specimen type, mass spectrometry method, data processing software, differential analysis techniques), and generates graphical summaries of study findings.